Opioid-induced hyperalgesia and analgesic tolerance can lead to dose escalation and inadequate pain treatment with l-opioid receptor agonists. Opioids cause tonic activation of glutamate NMDA receptors (NMDARs) at primary afferent terminals, increasing nociceptive input. However, the signaling mechanisms responsible for opioid-induced activation of pre-synaptic NMDARs in the spinal dorsal horn remain unclear. In this study, we determined the role of MAPK signaling in opioid-induced presynaptic NMDAR activation caused by chronic morphine administration. Whole-cell recordings of excitatory post-synaptic currents (EPSCs) were performed on dorsal horn neurons in rat spinal cord slices. Chronic morphine administration markedly increased the frequency of miniature EPSCs, increased the amplitude of monosynaptic EPSCs evoked from the dorsal root, and reduced the paired-pulse ratio of evoked EPSCs. These changes were fully reversed by an NMDAR antagonist and normalized by inhibiting extracellular signal-regulated kinase 1/ 2 (ERK1/2), p38, or c-Jun N-terminal kinase (JNK). Furthermore, intrathecal injection of a selective ERK1/2, p38, or JNK inhibitor blocked pain hypersensitivity induced by chronic morphine treatment. These inhibitors also similarly attenuated a reduction in morphine's analgesic effect in rats. In addition, coimmunoprecipitation assays revealed that NMDARs formed a protein complex with ERK1/2, p38, and JNK in the spinal cord and that chronic morphine treatment increased physical interactions of NMDARs with these three MAPKs. Our findings suggest that opioid-induced hyperalgesia and analgesic tolerance are mediated by tonic activation of pre-synaptic NMDARs via three functionally interrelated MAPKs at the spinal cord level.
Opioid analgesics are the mainstay of treatment of severe pain caused by cancer or tissue and nerve injury. However, repeated use of l-opioid receptor (MOR) agonists causes loss of analgesic efficacy and opioid dose escalation, which contributes to the current epidemic of opioid abuse in the United States. Also, acute and chronic opioid use can paradoxically increase pain sensitivity, termed opioidinduced hyperalgesia, in both animals and humans (Mao et al. 1994; Chia et al. 1999; Celerier et al. 2000; Chen et al. 2007) . Repeated morphine injections can progressively reduce the nociceptive threshold, which occurs in parallel with development of analgesic tolerance (Mao et al. 1994; Chen et al. 2007; Zhao et al. 2012) . Concurrent development of hyperalgesia associated with opioid use can be perceived as the diminished opioid analgesic effect (i.e., analgesic tolerance). Furthermore, intrathecal administration of glutamate N-methyl-D-aspartate receptor (NMDAR) antagonists blocks both hyperalgesia and analgesic tolerance induced by chronic morphine use (Mao et al. 1994; Zhao et al. 2012) , suggesting that increased NMDAR activity at the spinal cord level is essential for opioid-induced hyperalgesia and tolerance. Nevertheless, chronic morphine treatment reduces the activity of post-synaptic NMDARs in spinal dorsal horn neurons (Zhao et al. 2012) .
NMDARs are also expressed at primary afferent terminals in the spinal dorsal horn (Liu et al. 1994) . However, these NMDARs are not functionally active during the normal condition. After acute or chronic opioid exposure, presynaptic NMDARs become tonically activated, increasing glutamatergic input to spinal dorsal horn neurons (Zeng et al. 2006; Zhou et al. 2010; Zhao et al. 2012) . Hence, tonic activation of pre-synaptic NMDARs can increase nociceptive input from primary afferent nerves to spinal dorsal horn neurons, resulting in hyperalgesia and opioid tolerance (Zhou et al. 2010; Zhao et al. 2012) . However, how MOR stimulation leads to activation of pre-synaptic NMDARs in the spinal dorsal horn remains unclear.
Following MOR activation, MORs become phosphorylated by G protein receptor kinase, which initiates a barrestin-dependent desensitization process to terminate the MOR signaling (Keith et al. 1996; Bohn et al. 2004) . Furthermore, b-arrestin may act as a scaffolding protein and promote the stable association of signaling proteins with MORs to activate the MAPK pathways (McDonald et al. 2000; Luttrell et al. 2001) . Mice lacking b-arrestin 2 exhibit prolonged opioid analgesic effects and reduced tolerance to morphine (Bohn et al. 1999) , suggesting that arrestin/MAPK signaling contributes to opioid tolerance development. The three major MAPKs, extracellular signal-regulated kinases 1/ 2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK), are activated in primary sensory neurons by nociceptive stimuli (Obata and Noguchi 2004; Mizushima et al. 2005; Modol et al. 2015) . Although opioid-induced MAPK signaling is well documented (Fukuda et al. 1996; Belcheva et al. 2001) , there is currently no evidence showing whether MAPK signaling contributes to opioid-induced activation of presynaptic NMDARs at the spinal cord level.
In this study, we used a spinal cord slice preparation that has native MORs and preserves the intrinsic connection between primary afferents and dorsal horn neurons to define the role of ERK1/2, p38, and JNK in chronic morphine treatment-induced tonic activation of pre-synaptic NMDARs. We provide the first in vivo evidence that chronic morphine treatment potentiates the physical interaction between the NMDAR and ERK1/2, p38, and JNK in the spinal cord, leading to increased activity of pre-synaptic NMDARs at primary afferent terminals. This new information extends our understanding of signaling mechanisms involved in opioidinduced hyperalgesia and analgesic tolerance.
Materials and methods
Animal model and morphine treatment Adult male Sprague-Dawley rats [280-320 g; Harlan, Indianapolis, IN, USA; research resource identifiers (RRID): RGD_5508397] were used in our experiments. All procedures and protocols were approved by The University of Texas MD Anderson Cancer Center (approval #882-RN01) and were performed in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The timeline of experimental procedures and number of animals used for each protocol were specified in Fig. 1 . To induce opioid hyperalgesia and analgesic tolerance, morphine sulfate (West Ward Pharmaceuticals, Eatontown, NJ) was intraperitoneally injected into the rats at 5 mg/kg twice a day for eight consecutive days (Chen et al. 2007; Zhao et al. 2012) .
Intrathecal catheterization and drug delivery
A polyethylene PE10 catheter was implanted in the lumbar subarachnoid space in each rat under isoflurane-induced anesthesia according to the method described previously (Chen and Pan 2006a) . Briefly, each animal was placed prone on a stereotaxic frame, and a small incision was made at the back of the neck. The catheter was inserted after a small puncture was made in the atlantooccipital membrane of the cisterna magna. The caudal tip of the catheter was then advanced and reached the lumbar enlargement of the spinal cord. To minimize animal's suffering, 1% lidocaine was injected around the incision site during the brief surgery. The animals were allowed to recover for 7 days before intrathecal injection, and no other medications were administered. Rats exhibiting neurological deficits (e.g., paralysis) or poor grooming were promptly killed via CO 2 asphyxiation. In 43 rats instrumented with intrathecal catheters, four rats were killed as a result of motor weakness and impairment. U0126 (5 lg; EMD-Calbiochem, La Jolla, CA, USA), 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580, 5 lg; EMD-Calbiochem), and SP600125 (30 lg; Cayman Chemical, Ann Arbor, MI, USA) were dissolved in dimethylsulfoxide and intrathecally injected 20 min before morphine administration on each testing day (days 1-8).
Spinal cord slice preparation and electrophysiological recordings of dorsal horn neurons The lumbar spinal cords were rapidly removed from the rats via laminectomy under isoflurane-induced anesthesia. Each spinal cord was immediately placed in ice-cold sucrose artificial cerebrospinal fluid containing (in mM) 3.6 KCl, 1.2 MgCl 2 , 2.5 CaCl 2 , 1.2 NaH 2 PO 4 , 25.0 NaHCO 3 , 234 sucrose, and 12.0 glucose presaturated with 95% O 2 and 5% CO 2 . The spinal cord was then placed in a shallow groove formed in an agar block and glued onto the stage of a vibratome (Leica, Wetzlar, Germany). Transverse slices of the spinal cords (400 lm thick) were cut in ice-cold sucrose artificial cerebrospinal fluid and pre-incubated in Krebs solution containing (in mM) 3.6 KCl, 1.2 MgCl 2 , 117.0 NaCl, 2.5 CaCl 2 , 1.2 NaH 2 PO 4 , 11.0 glucose, and 25.0 NaHCO 3 oxygenated with 95% O 2 and 5% CO 2 at 34°C for at least 1 h before being transferred to a recording chamber. The spinal cord slice was placed in an incubation chamber and continuously perfused with Krebs solution at 5 mL/min and 34°C maintained by an inline solution heater and a temperature controller.
The spinal cord lamina II, a translucent region in the superficial dorsal horn, was identified in each slice under an upright fixed-stage microscope (BX50WI; Olympus, Tokyo, Japan) with differential interference contrast/infrared illumination. Neurons in the lamina II outer zone were visualized and selected for whole-cell recordings because they are important for nociceptive transmission Wang et al. 2018) . A previous study shows that most lamina II neurons are glutamate-releasing excitatory interneurons (Santos et al. 2007) , and these neurons form networks that play a critical role in transmitting nociceptive information from the primary afferents. The impedance of the glass electrode was 4-7 MO when a pipette was filled with an internal solution containing (in mM) 135 potassium gluconate, 0.5 CaCl 2 , 5 KCl, 2.0 MgCl 2 , 5.0 HEPES, 5.0 ATP-Mg, 0.5 Na-GTP, 5.0 EGTA, and 10 QX314 (adjusted to pH 7.25 with 1.0 M KOH, 280-300 mOsm).
Excitatory post-synaptic currents (EPSCs) were recorded at a holding potential of -60 mV using whole-cell voltage-clamp techniques. The input resistance was monitored, and the recording was abandoned if it changed by more than 15%. EPSCs were recorded using an amplifier (MultiClamp 700A; Axon Instruments, Foster City, CA, USA), filtered at 1-2 kHz, and digitized at 10 kHz. Miniature EPSCs (mEPSCs) were recorded in the presence of 1 lM tetrodotoxin (Zhou et al. 2010; Chen et al. 2014) . Because our whole-cell recording was done at a holding potential of À60 mV and in the presence of 1.2 mM Mg 2+ (in the Krebs solution), the post-synaptic NMDARs were largely closed. To evoke glutamate release from primary afferent nerves, a bipolar tungsten electrode connected to a stimulator (0.2 ms, 0.3-0.6 mA, 0.1 Hz; Grass Instruments, Quincy, MA, USA) was used to electrically stimulate the dorsal root, and monosynaptic EPSCs were identified on the basis of the constant latency and absence of conduction failure of evoked EPSCs in response to 20-Hz electrical stimulation (Zhou et al. 2010; Xie et al. 2017b) . To calculate the paired-pulse ratio (PPR), two EPSCs were evoked by a pair of stimuli at 50-ms intervals. The PPR was expressed as the ratio of the amplitude of the second synaptic response to the amplitude of the first synaptic response (Zhao et al. 2012; Xie et al. 2017b) . All the drugs were prepared in artificial cerebrospinal fluid immediately before the experiments and delivered via syringe pumps to reach their final concentrations. 2-amino-5-phosphonopentanoic acid (AP5) and tetrodotoxin were purchased from Hello Bio (Princeton, NJ, USA).
Behavioral assessment of nociception
To quantify the mechanical nociceptive threshold in the rats, a paw pressure test on a hindpaw was conducted using an analgesiometer (Ugo Basile, Varese, Italy). The device was activated by pressing a foot pedal to generate a constantly increasing force. When the animal displayed pain by either withdrawing its paw or vocalizing, the device was immediately inactivated, and the animal's withdrawal threshold was read on the scale (Chen et al. 2007; Zhao et al. 2012) . A maximum of 400 g of pressure was used as a cutoff to avoid tissue injury to the rats. To assess thermal sensitivity, rats were placed on the glass surface of a thermal testing apparatus (IITC Life Science, Woodland Hills, CA, USA) and allowed to acclimate for 30 min before testing. The temperature of the glass surface was maintained constant at 30°C. A mobile radiant heat source located under the glass was focused onto a hindpaw of each rat. The paw withdrawal latency was recorded using a timer, and the hindpaw was tested twice to obtain the average. A cutoff of 30 s was set to prevent tissue damage (Chen and Pan 2006b; Li et al. 2016 ).
Co-immunoprecipitation
After treatment with morphine and vehicle for 8 days, the dorsal quadrants of lumbar spinal cord tissues were quickly removed from rats anesthetized with 3% isoflurane. The spinal tissues were dissected and homogenized in ice-cold immunoprecipitation buffer (50 mM Tris [pH7.4], 250 mM NaCl, 20 mM NaF, 1 mM Na 3 VO 4 , 10% glycerol, 0.5% NP-40, 10 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, and 2 mM benzamide) containing cocktails of protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Samples were then put on ice for 30 min with constant shaking. Lysates were centrifuged at 13 000 g for 30 min at 4°C. The supernatant was carefully collected, and the protein concentration was measured using a DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). The soluble fraction was incubated at 4°C overnight with Protein A/G beads (#16-266; Millipore, Darmstadt, Germany) pre-bound to a mouse anti-GluN1 antibody (#75-272, 1 : 1000; NeuroMab, Davis, CA, USA; RRID: AB_11000180). Protein A/G beads pre-bound to mouse IgG were used as controls. Samples were washed three times with an immunoprecipitation (IP) buffer and then immunoblotted. The following antibodies were selected for immunoblotting: rabbit anti-GluN1 (#G-8913, 1 : 1000; Sigma-Aldrich; RRID: AB_259978), rabbit anti-ERK1/2 (#4695, 1 : 1000; Cell Signaling Technology, Danvers, MA, USA; RRID: AB_390779), rabbit anti-p38 (#8690, 1 : 1000; Cell Signaling Technology; RRID: AB_10999090), and rabbit anti-SAPK/JNK (#9252, 1 : 1000; Cell Signaling Technology; RRID:AB_2250373). The specificity of these antibodies was validated in previous studies (Rudhard et al. 2003; Brady et al. 2017; Li et al. 2017; Sun et al. 2017) . For immunoblots, lysates were separated on a 4-12% gradient sodium dodecyl sulfate-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane. The membrane was blocked by 5% blotting-grade buffer (#170-6404; Bio-Rad). After the antibody incubation, the membrane was washed three times with Tris-buffered saline with Tween 20 (#9997S; Cell Signaling Technology). An enhanced chemiluminescence kit (#PI34580; Fisher Scientific, Lenexa, KS, USA) was used to detect the protein band, which was visualized and quantified using an Odyssey Fc Imager (LI-COR Biotechnology, Lincoln, NE, USA).
Study design and data analysis
Data were expressed as means AE SEM. No statistical methods were used to predetermine sample sizes for the studies, but our sample sizes were similar to those generally employed in the field. The animals were assigned (1 : 1 allocation) to the control and treatment groups, and no randomization methods were used. We did not exclude any animals from data analysis and did not use any test for outliers on the data. The investigators performing electrophysiological and behavioral experiments were blinded to drug treatment. In electrophysiological experiments, only one neuron was recorded in each tissue slice, and at least three rats were used in each group. The amplitude of 10 consecutive evoked EPSCs was analyzed and averaged using the Clampfit 10.0 software program (Axon Instruments). mEPSCs were analyzed offline using the Mini Analysis peak detection program (Synaptosoft, Leonia, NJ, USA). D'Agostino-Pearson normality test was used to assess the normality of data. The Student's t-test was used to compare two groups, and one-way analysis of variance followed by Dunnett's post hoc test was used to compare more than two groups. Two-way analysis of variance followed by Bonferroni's post hoc test was used to determine the difference in development of hyperalgesia and opioid tolerance between the vehicle-and morphine-treated rats. Statistical analyses were performed using Prism software (version 7; GraphPad Software Inc., La Jolla, CA, USA). p < 0.05 was considered to be statistically significant.
Results
ERK1/2 mediates chronic morphine-induced increases in pre-synaptic NMDAR activity in the spinal cord We first determined whether ERK1/2 plays a role in increased pre-synaptic NMDAR activity in the spinal cord induced by chronic morphine treatment. Pre-synaptic ERK signaling plays a role in synaptic plasticity in the hippocampus (Vara et al. 2009) , and pre-synaptic ERK1/2 is important for the control of central glutamatergic synapses (Sindreu et al. 2011) . We recorded mEPSCs in spinal cord lamina II neurons, which reflect quantal glutamate release from presynaptic terminals (Chen et al. 2014; Xie et al. 2017a) . Bath application of 50 lM AP5, a specific NMDAR antagonist, rapidly normalized the increased frequency of mEPSCs in lamina II neurons obtained from morphine-treated rats (baseline, 6.45 AE 0.60 Hz; AP5, 4.17 AE 0.45 Hz; n = 11 neurons, Fig. 2a and b) . Bath application of AP5 does not affect the frequency or amplitude of mEPSCs in lamina II neurons from control rats (Zhou et al. 2010; Zhao et al. 2012) . These results suggest that chronic morphine potentiates pre-synaptic NMDAR activity of spinal dorsal horn neurons, a finding similar to that in our previous study (Zhao et al. 2012) . Also, U0126 is a highly selective ERK1/2 inhibitor used to study ERK1/2-mediated signaling (Favata et al. 1998; Arana-Argaez et al. 2010) . Pre-treatment with U0126 (10 lM for 1 h) significantly reduced the baseline frequency (3.00 AE 0.26 Hz vs. 6.45 AE 0.60 Hz), but not the amplitude of mEPSCs in lamina II neurons in spinal cord slices obtained from morphine-treated rats (n = 10 neurons, 6.45 AE 0.60 Hz vs. 3.00 AE 0.26 Hz, p < 0.05; Fig. 2b and d). In these 10 neurons, subsequent application of 50 lM AP5 had no effect on the frequency or amplitude of mEPSCs ( Fig. 2c and d) .
The synapse formed by central terminals of primary afferent neurons and spinal dorsal horn neurons is essential for nociceptive transmission and modulation by opioids (Chen and Pan 2006a; Zhou et al. 2008 Zhou et al. , 2010 . We thus determined whether ERK1/2 is involved in morphineinduced increases in the activity of NMDARs expressed at primary afferent nerve terminals in the spinal dorsal horn. Monosynaptic EPSCs of spinal dorsal horn neurons were evoked from the dorsal root, which represents elicited glutamate released from primary afferent terminals (Zhou et al. 2010; Xie et al. 2017b) . Bath application of 50 lM AP5 considerably reduced the amplitude of monosynaptic EPSCs (363.7 AE 21.6 pA vs. 441.4 AE 23.9 pA) and increased the PPR (0.76 AE 0.06 vs. 0.65 AE 0.05) of monosynaptically evoked EPSCs of lamina II neurons obtained from morphine-treated rats (n = 10 neurons, Fig. 3a-c) . These data are consistent with those in our previous study demonstrating opioid-induced tonic activation of NMDARs at primary afferent terminals (Zhao et al. 2012) . After pre-treatment of lamina II neurons from morphine-treated rats with U0126 (10 lM for 1 h), bath application of 50 lM AP5 no longer had an effect on the amplitude (n = 10 neurons) or PPR of monosynaptic EPSCs (n = 9 neurons, Fig. 3d-f) . Taken together, these data indicate that ERK1/2 plays a critical role in opioid-induced tonic activation of pre-synaptic NMDARs in the spinal cord.
p38 involved in morphine-induced pre-synaptic NMDAR activation in the spinal cord We next determined whether the p38 MAPK is involved in chronic morphine-induced increases in pre-synaptic NMDAR activity in the spinal cord. p38 is expressed presynaptically (Nakata et al. 2005) , and SB203580 is a pyridinyl imidazole inhibitor commonly used to study p38 activity in vitro and in vivo (Arana-Argaez et al. 2010; Jin et al. 2013) . Pre-treatment with SB203580 (5 lM for 1 h) caused a large reduction in the baseline frequency of mEPSCs in spinal lamina II neurons obtained from morphine-treated rats (3.63 AE 0.41 Hz vs. 6.45 AE 0.60 Hz; n = 10 neurons, p < 0.05; Figs 2b and 4b). In these neurons, further treatment with AP5 failed to affect the frequency or amplitude of mEPSCs (n = 10 neurons, Fig. 4a  and b) .
We also examined whether p38 inhibition affects morphine-induced activation of NMDARs at primary afferent terminals. After treatment of spinal lamina II neurons obtained from morphine-treated rats with SB203580 (5 lM for 1 h), subsequent bath application of 50 lM AP5 had no effect on the amplitude of evoked monosynaptic EPSCs (n = 10 neurons, Fig. 4c and e) or the PPR of monosynaptic EPSCs (n = 9 neurons, Fig. 4d and e) . These results suggest that p38 mediates opioidinduced tonic activation of NMDARs at primary afferent terminals. JNK participates in morphine-induced increases in pre-synaptic NMDAR activity in the spinal cord We then examined whether JNK is involved in increased presynaptic NMDAR activity in the spinal dorsal horn in morphine-treated rats. JNK2 is expressed pre-synaptically and plays a role in NMDAR-mediated glutamate release in the cortex (Nistico et al. 2015) . SP600125 is an anthrapyrazolone capable of inhibiting JNK1, JNK2, and JNK3 with high affinity Kocab et al. 2015) . In lamina II neurons obtained from morphine-treated rats, pretreatment with SP600125 (40 lM for 1 h) significantly reduced the frequency (4.40 AE 0.44 Hz vs. 6.45 AE 0.60 Hz), but not the amplitude, of mEPSCs (n = 10 neurons, Fig. 2b and 5b ). In the same neurons, subsequent bath application of AP5 did not significantly affect the frequency or amplitude of mEPSCs ( Fig. 5a and b) .
In addition, after treatment of lamina II neurons from morphine-treated rats with SP600125, bath application of AP5 (50 lM) did not have a significant effect on the amplitude of monosynaptically evoked EPSCs (n = 10 neurons, Fig. 5c and e) or the PPR of monosynaptic EPSCs (n = 9 neurons, Fig. 5d and e). These findings suggest that increased JNK activity critically contributes to opioid-induced tonic activation of pre-synaptic NMDARs in the spinal dorsal horn.
MAPK signaling at the spinal cord level mediates the development of opioid-induced hyperalgesia and tolerance
The electrophysiological results in this study suggest that ERK1/2, p38, and JNK are all involved in opioid-induced tonic activation of pre-synaptic NMDARs, which can increase nociceptive input to spinal dorsal horn neurons. To determine whether these three MAPKs are similarly involved in opioid-induced hyperalgesia and tolerance, we determined the effects of intrathecal administration of individual MAPK inhibitors on hyperalgesia and tolerance caused by chronic morphine administration. We induced morphine analgesic tolerance in the rats via daily intraperitoneal injection of morphine (5 mg/kg twice a day) for eight consecutive days (Chen et al. 2007; Zhao et al. 2012) . We also intrathecally injected 5 lg of U0126, 5 lg of SB203580, 30 lg of SP600125, or a vehicle control (in a volume of 10 ll) 20 min before each morphine administration in separate groups of rats. The intrathecal doses of MAPK inhibitors were derived from previous studies (Daulhac et al. 2006; Chen et al. 2008; Tsai et al. 2009 ). Original recording traces show the lack of the effect of AP5 on pairedpulse ratio of monosynaptic EPSCs of a lamina II neuron from spinal cord slices pre-treated with 10 lM U0126 in morphine-treated rats. (f) Group data show a lack of effect of 50 lM AP5 on the amplitude (n = 10 neurons from 4 rats) and PPR (n = 9 neurons from four rats) of monosynaptic EPSCs of lamina II neurons pre-treated with 10 lM U0126 in spinal cord slices from morphine-treated rats. Data are presented as means AE SEM. *p < 0.05 when compared with respective baseline controls (one-way ANOVA followed by Dunnett's post hoc test).
We measured their withdrawal thresholds in response to noxious pressure and thermal stimuli 30 min before (baseline) and 30 min after morphine injection daily. In vehicletreated rats, daily morphine administration caused a gradual reduction in the baseline pressure and thermal withdrawal thresholds, indicating the presence of mechanical and thermal hyperalgesia (n = 9 rats, Fig. 6a and b) . In contrast, treatment with U0126 (n = 7 rats), SB203580 (n = 7 rats), or SP600125 (n = 8 rats) blocked the decrease in the baseline withdrawal thresholds induced by chronic morphine administration ( Fig. 6a and b) . Furthermore, when 5 lg of U0126, 5 lg of SB203580, and 30 lg of SP600125 were combined for intrathecal injection, no additive effect on morphineinduced mechanical and thermal hyperalgesia was observed compared with a single MAPK inhibitor (n = 8 rats, Fig. 6a  and b) .
Also, in vehicle-treated rats, intraperitoneal injection of 5 mg/kg morphine on day 1 produced robust increases in the pressure and thermal withdrawal thresholds. Daily morphine administration caused gradual attenuation of the analgesic effect of morphine. By day 6, morphine produced no analgesic effect, indicating the development of analgesic tolerance (n = 9 rats, Fig. 6c and d) . In comparison, treatment with U0126 (n = 7 rats), SB203580 (n = 7 rats), or SP600125 (n = 8 rats) largely attenuated the reduction in the analgesic effect of morphine ( Fig. 6c and d) . Even by day 8, intraperitoneal injection of 5 mg/kg morphine still markedly increased the mechanical and thermal withdrawal thresholds in rats given any one of the three MAPK inhibitors. In addition, when U0126, SB203580, and SP600125 were combined for intrathecal injection, no additive on the development of morphine-induced analgesic tolerance effect was detected compared with a single MAPK inhibitor (n = 8 rats, Fig. 6c and d) . These data suggest that increased activity of ERK1/2, p38, and JNK at the spinal level is required for the development of opioid-induced hyperalgesia and analgesic tolerance.
Chronic morphine treatment increases the physical interaction between MAPKs and NMDARs in the spinal cord
Because our electrophysiological and behavioral data unexpectedly showed that ERK1/2, p38, and JNK are similarly involved in opioid-induced pre-synaptic NMDAR activation, hyperalgesia, and analgesic tolerance, we reasoned whether show the lack of effect of 50 lM AP5 on the amplitude (n = 10 neurons from three rats) and PPR (n = 9 neurons from three rats) of monosynaptic EPSCs in lamina II neurons from spinal cord slices pretreated with SB203580 in morphine-treated rats. Data are presented as means AE SEM. chronic morphine treatment promotes the association of these three functionally redundant MAPKs with NMDARs at the spinal cord level. To determine the interaction between the NMDAR and ERK1/2, p38, and JNK in vivo, we conducted co-immunoprecipitation (co-IP) assays using total protein extracts of rat dorsal spinal cords obtained from vehicle-and chronic morphine-treated rats. We used an anti-GluN1 antibody for co-IP assays because GluN1 is an obligatory subunit of NMDARs. Co-IP analysis showed that the antiGluN1 antibody, but not an irrelevant anti-immunoglobulin G (anti-IgG) antibody, precipitated ERK1/2, p38, and JNK proteins in spinal cord protein extracts (Fig. 7a and b) . Furthermore, co-IP analysis demonstrated that the antiGluN1 antibody precipitated considerably more ERK1/2, p38, and JNK proteins in the spinal protein extracts from chronic morphine-treated than from vehicle-treated rats (p < 0.05, n = 6 rats per group; Fig. 7a and b) . However, the total protein amounts (i.e., input controls) for GluN1, ERK1/2, p38, and JNK in the spinal cord did not differ significantly between the vehicle-treated and morphinetreated groups (Fig. 7a and b) . These results indicate that NMDARs form a large protein complex with ERK1/2, p38, and JNK at the spinal cord level and that chronic opioid treatment promotes the association of NMDARs with the three MAPKs.
Discussion
Our current understanding of the dynamic opioid signaling mechanism remains fragmented, and the in vitro opioid signaling is often not directly linked with the in vivo physiological or pharmacological effects of opioids. MORs at the spinal cord level are essential for the analgesic effect of systemically administered opioids (Chen and Pan 2006a) . Activation of MORs typically causes G protein-mediated inhibition of voltage-activated calcium channels, resulting in attenuation of nociceptive glutamatergic transmission in the spinal dorsal horn, producing an analgesic effect (Wu et al. 2004; Zhang et al. 2016) . On the other hand, b-arrestinmediated signaling is involved in rapid attenuation of opioid analgesic actions and opioid tolerance (Bohn et al. 1999; Pierce and Lefkowitz 2001) . Arrestin may function as MAPK scaffolds and facilitate activation of MAPKs (Lefkowitz and Shenoy 2005; Song et al. 2009 ). ERK1/2, p38, and JNK are the most extensively studied MAPKs. In general, ERK1/2 is preferentially stimulated in response to exposure to growth factors and phorbol esters, whereas JNK and p38a/b are more responsive to stress stimuli, including osmotic shock and cytokine stimulation (Pearson et al. 2001) . It has been recognized that phosphorylated arrestin-bound MOR complexes not only inactivate MOR's effects but also recruit MAPK signaling (Lefkowitz and Shenoy 2005) . In this study, we showed that inhibiting the activity of ERK1/2, p38, or JNK at the spinal cord level not only preserved the analgesic effect of morphine but also abolished morphine-induced hyperalgesia. Consistent with our results, morphine tolerance is blocked in JNK2-knockout mice (Melief et al. 2010) . Our findings suggest that ERK1/2, p38, and JNK play a critical role in the development of opioid-induced hyperalgesia and analgesic tolerance.
A striking finding of our study is that increased activity of ERK1/2, p38, and JNK is required for morphine-induced tonic activation of pre-synaptic NMDARs in the spinal cord. NMDARs at the spinal cord level play an essential role in both the development and maintenance of opioid-induced hyperalgesia and tolerance (Trujillo and Akil 1991; Mao et al. 1994; Zhao et al. 2012) . We showed that inhibiting ERK1/2, p38, or JNK activity completely blocked opioidinduced activation of pre-synaptic NMDARs in the spinal dorsal horn. We previously reported that even brief stimulation of MORs can trigger long-lasting NMDAR-mediated glutamate release from primary afferent terminals in the spinal cord (Zhou et al. 2010) . Chronic opioid treatment can Fig. 6 Inhibition of extracellular signal-regulated kinase 1/2, p38, or cJun N-terminal kinase activity at the spinal cord level attenuates both opioid-induced hyperalgesia and analgesic tolerance caused by chronic morphine treatment. (a) Time course of changes in the baseline nociceptive withdrawal threshold in response to a noxious pressure stimulus of the hindpaw in rats given systemic morphine plus intrathecal injections of a vehicle (n = 9 rats), 5 lg U0126 (n = 7 rats), 5 lg SB203580 (n = 7 rats), 30 lg SP600125 (n = 8 rats), or combination of 5 lg U0126, 5 lg SB203580, and 30 lg SP600125 (n = 8 rats). (b) Time course of changes in the baseline withdrawal latency measured with a noxious heat stimulus in rats given systemic morphine plus intrathecal injections of a vehicle (n = 9 rats), 5 lg U0126 (n = 7 rats), 5 lg SB203580 (n = 7 rats), 30 lg SP600125 (n = 8 rats), or combination of 5 lg U0126, 5 lg SB203580, and 30 lg SP600125 (n = 8 rats). (c) Time course of the analgesic effect of morphine on the mechanical nociceptive withdrawal threshold in rats given intrathecal injections of a vehicle (n = 9 rats), 5 lg U0126 (n = 7 rats), 5 lg SB203580 (n = 7 rats), 30 lg SP600125 (n = 8 rats), or combination of 5 lg U0126, 5 lg SB203580, and 30 lg SP600125 (n = 8 rats). (d) Time course of the analgesic effect of morphine on the heat withdrawal latency in rats given intrathecal injections of a vehicle (n = 9 rats), 5 lg U0126 (n = 7 rats), 5 lg SB203580 (n = 7 rats), 30 lg SP600125 (n = 8 rats), or combination of 5 lg U0126, 5 lg SB203580, and 30 lg SP600125 (n = 8 rats). The baseline withdrawal threshold was measured before morphine injection each day, and the analgesic effect of morphine was tested 30 min after each morphine injection (5 mg/kg, intraperitoneal). Data are presented as means AE SEM. *p < 0.05 when compared with the corresponding baseline value or morphine effect in the vehicle control group (two-way ANOVA followed by Bonferroni's post hoc test).
sustain activation of pre-synaptic NMDARs to increase nociceptive input to the spinal dorsal horn, thereby producing prolonged hyperalgesia and opposing the opioid's analgesic effects (i.e., causing tolerance). Notably, chronic morphine treatment increases the phosphorylation of ERK1/2, p38, and JNK in primary sensory neurons (Ma et al. 2001; Chen et al. 2008) . Also, ERK activation can stimulate NMDAR activity in the brain (Nateri et al. 2007) , and pre-synaptic JNK2 regulates NMDAR-dependent glutamate release in the brain (Nistico et al. 2015) . Both GluN2A-or GluN2B-containing NMDARs are involved in the increased pre-synaptic NMDAR activity by chronic morphine treatment (Zhao et al. 2012) . The increased pre-synaptic NMDAR activity after chronic morphine exposure is abolished by inhibition of protein kinase C (PKC) and MAPKs, suggesting that increased NMDAR phosphorylation may enhance presynaptic NMDAR function by promoting NMDAR trafficking and surface expression and by reducing the Mg 2+ block (Chen and Huang 1992; Lan et al. 2001; Zhao et al. 2012; Chen et al. 2018) . The sources of endogenous glutamate and glycine that cause tonic activation of pre-synaptic NMDARs during chronic morphine treatment are not clear. Glutamate may originate from the same primary afferent nerve terminals on which the NMDARs are expressed or from excitatory interneurons in the superficial dorsal horn (Wang et al. 2018) . Also, glutamate and glycine may diffuse from an adjacent active terminal or reduced glutamate/glycine reuptake as a result of reduced glutamate/glycine transporter activity (Mao et al. 2002) . Our present findings reveal a critical role of pre-synaptic MAPK signaling in opioidinduced stimulation of NMDARs in the spinal cord.
Another salient finding of our study is that NMDARs and ERK1/2, p38, and JNK can form a protein complex in the spinal cord and that chronic morphine treatment substantially increases the interaction of pre-synaptic NMDARs with the three MAPKs. This increased association may lead to presynaptic NMDAR phosphorylation to potentiate NMDAR activity in the spinal dorsal horn. It remains uncertain how the three major groups of distinctly regulated MAPK cascades converge to NMDARs in the spinal cord after MOR stimulation, although the increased pre-synaptic NMDAR phosphorylation seems to be the common downstream signaling mechanism for the three MAPKs. The signaling cascade and/or crosstalk among the three MAPKs may be necessary for potentiation of pre-synaptic NMDAR phosphorylation and activity in the spinal dorsal horn during the development of opioid-induced hyperalgesia and tolerance. In cell lines, phosphorylated p38 is capable of forming a complex with ERK1/2 (Zhang et al. 2001) . In addition, PKC inhibition can block opioid-induced pre-synaptic NMDAR activation, hyperalgesia, and tolerance (Zhao et al. 2012) . PKC is considered an early signaling component in Fig. 7 The physical interaction of NMDA receptors (NMDARs) among extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK) in the spinal cord is enhanced by chronic morphine treatment. (a) Co-immunoprecipitation analysis shows the protein-protein interaction between the NMDAR subunit GluN1 and ERK1/2, p38, and JNK in the total protein extracts of dorsal spinal cords tissues obtained from rats given a vehicle (V) or morphine (M) for 8 days. Proteins were initially immunoprecipitated with a mouse anti-GluN1 or anti-IgG antibody. Western immunoblotting was then performed using rabbit anti-GluN1, rabbit anti-ERK1/2, rabbit anti-p38, or rabbit anti-JNK antibodies. IgG and input (tissue lysates only, without immunoprecipitation) were used as negative and positive controls, respectively. The molecular marker (mm) is shown on the left. (b) Summary data show the effect of morphine treatment on the amounts of GluN1-precipitated protein complexes containing ERK1/2, p38, and JNK in the dorsal spinal cord (n = 6 rats/group). The amount of ERK1/2, p38, and JNK protein was normalized according to that of GluN1 in the same samples, and the mean value of ERK1/2, p38, JNK, andGluN1 protein levels in vehicletreated rats was considered to be 1. Data are presented as means AE SEM. *p < 0.05 when compared with the vehicle-treated group (paired Student's t-test).
the opioid-induced MAPK signaling pathway (Fukuda et al. 1996; Belcheva et al. 2001) . In cell lines, PKC activity is required for both MOR-induced JNK activation and ERK1/2 phosphorylation (Zheng et al. 2008; Kuhar et al. 2015) . Although all MOR agonists activate ERK signaling, in vitro experiments suggest that morphine uses the PKC pathway to induce ERK phosphorylation, whereas etorphine and fentanyl use the b-arrestin pathway (Zheng et al. 2008) . Further studies are warranted to determine whether b-arrestin and PKC are required for the recruitment of MAPKs to NMDARs in the spinal cord during chronic opioid treatment.
In summary, our study provides important new evidence that chronic opioid treatment enhances the physical association of NMDARs with MAPKs, including ERK1/2, p38, and JNK, in the spinal cord. These three functionally interrelated MAPKs critically contribute totonic activation of pre-synaptic NMDARs in the spinal cord, which is responsible for opioidinduced hyperalgesia and analgesic tolerance. This new information is important in understanding the underlying signaling mechanisms of opioid-induced hyperalgesia and analgesic tolerance. Clinically used NMDAR antagonists are effective in reducing opioid tolerance in patients (Mercadante et al. 2000; Xuerong et al. 2008) . However, these drugs often produce intolerable adverse effects. MAPKs may be targeted for inhibiting opioid-induced abnormal pre-synaptic NMDAR activation, thereby improving opioid analgesic efficacy and minimizing opioid side effects.
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